Viral vectors in malaria vaccine development

Parasite Immunology

Volumn 31, Issue 9, 2009, Pages 501-519

  Limbach, K J ^a   Richie, T L ^a  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

Author keywords

Malaria; Vaccine; Viral vectors

Indexed keywords

AD35.CS.01 VACCINE; ADENOVIRUS VECTOR MALARIA VACCINE; ALPHAVIRUS VACCINE; CANARYPOX VIRUS VACCINE; DNA VACCINE; FLAVIVIRUS VACCINE; FOWLPOX VIRUS VACCINE; MALARIA VACCINE; MAREK DISEASE VACCINE; MORBILLIVIRUS VACCINE; NMRC M3V AD PFCA VACCINE; NYVAC PF7 VACCINE; PARVOVIRUS VECTOR VACCINE; POXVIRUS VECTOR MALARIA VACCINE; RECOMBINANT PROTEIN VACCINE; RECOMBINANT VACCINE; RTS,S VACCINE; UNCLASSIFIED DRUG; VACCINE; VACCINIA VACCINE; VIRUS VACCINE; VIRUS VECTOR; VIRUS VECTOR VACCINE;

ADENOVIRUS; ALPHA VIRUS; ATTENUATION; CANARYPOX VIRUS; CELLULAR IMMUNITY; CLINICAL TRIAL; DNA SEQUENCE; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; ENZYME LINKED IMMUNOSPOT ASSAY; FOWLPOX VIRUS; GENE DELETION; GENE DELIVERY SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; INFECTION RISK; LIVER; LOW DRUG DOSE; LOW GRADE FEVER; MALARIA; MARDIVIRUS; NONHUMAN; PLASMODIUM; POXVIRUS; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT; VACCINATION; VACCINIA VIRUS; VIRUS REPLICATION;

ADENOVIRIDAE; GENETIC VECTORS; HUMANS; MALARIA; MALARIA VACCINES; VACCINIA VIRUS;

ADENOVIRIDAE; ANIMALIA; POXVIRIDAE;

EID: 68949093653     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/j.1365-3024.2009.01141.x     Document Type: Review

References (137)

1. Patarroyo ME, Romero P, Torres ML, et al. Induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature 1987 328 : 629 632.
2. Zavala F, Tam JP, Barr PJ, et al. Synthetic peptide vaccine confers protection against murine malaria. J Exp Med 1987 166 : 1591 1596.
3. Herrera MA, Rosero F, Herrera S, et al. Protection against malaria in Aotus monkeys immunized with a recombinant blood-stage antigen fused to a universal T-cell epitope: correlation of serum gamma interferon levels with protection. Infect Immun 1992 60 : 154 158.
4. Knapp B, Hundt E, Enders B Küpper HA. Protection of Aotus monkeys from malaria infection by immunization with recombinant hybrid proteins. Infect Immun 1992 60 : 2397 2401.
5. Ling IT, Ogun SA Holder AA. Immunization against malaria with a recombinant protein. Parasite Immunol 1994 16 : 63 67.
6. Chang SP, Case SE, Gosnell WL, et al. A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. Infect Immun 1996 64 : 253 261.
7. Rénia L, Ling IT, Marussig M, Miltgen F, Holder AA Mazier D. Immunization with a recombinant C-terminal fragment of Plasmodium yoelii merozoite surface protein 1 protects mice against homologous but not heterologous P. yoelii sporozoite challenge. Infect Immun 1997 65 : 4419 4423.
8. Anders RF, Crewther PE, Edwards S, et al. Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi. Vaccine 1998 16 : 240 247.
9. Daubersies P, Thomas AW, Millet P, et al. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nat Med 2000 6 : 1258 1263. Erratum in: Nat Med 2000; 6 (12): 1412.
10. Kumar S, Collins W, Egan A, et al. Immunogenicity and efficacy in Aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1. Infect Immun 2000 68 : 2215 2223.
11. Hisaeda H, Saul A, Reece JJ, et al. Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys. J Infect Dis 2002 185 : 657 664.
12. Stowers AW, Kennedy MC, Keegan BP, Saul A, Long CA Miller LH. Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect Immun 2002 70 : 6961 6967.
13. Wang L, Kedzierski L, Wesselingh SL Coppel RL. Oral immunization with a recombinant malaria protein induces conformational antibodies and protects mice against lethal malaria. Infect Immun 2003 71 : 2356 2364.
14. Burns JM Jr., Flaherty PR, Nanavati P Weidanz WP. Protection against Plasmodium chabaudi malaria induced by immunization with apical membrane antigen 1 and merozoite surface protein 1 in the absence of gamma interferon or interleukin-4. Infect Immun 2004 72 : 5605 5612.
15. Goschnick MW, Black CG, Kedzierski L, Holder AA Coppel RL. Merozoite surface protein 4/5 provides protection against lethal challenge with a heterologous malaria parasite strain. Infect Immun 2004 72 : 5840 5849.
16. Carvalho LJ, Alves FA, Bianco C Jr., et al. Immunization of Saimiri sciureus monkeys with a recombinant hybrid protein derived from the Plasmodium falciparum antigen glutamate-rich protein and merozoite surface protein 3 can induce partial protection with Freund and Montanide ISA720 adjuvants. Clin Diagn Lab Immunol 2005 12 : 242 248.
17. Valderrama-Aguirre A, Quintero G, Gómez A, et al. Antigenicity, immunogenicity, and protective efficacy of Plasmodium vivax MSP1 PV200l: a potential malaria vaccine subunit. Am J Trop Med Hyg 2005 73 (5 Suppl. 16 24.
18. Heppner DG Jr., Kester KE, Ockenhouse CF, et al. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine 2005 23 : 2243 2250.
19. Li S, Locke E, Bruder J, et al. Viral vectors for malaria vaccine development. Vaccine 2007 25 : 2567 2574.
20. Stewart VA, McGrath SM, Dubois PM, et al. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infect Immun 2007 75 : 2283 2290.
21. Sedegah M, Chiang CH, Weiss WR, et al. Recombinant pseudorabies virus carrying a Plasmodium gene: herpesvirus as a new live viral vector for inducing T- and B-cell immunity. Vaccine 1992 10 : 578 584.
22. Rodrigues M, Li S, Murata K, et al. Influenza and vaccinia viruses expressing malaria CD8+ T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective immunity. J Immunol 1994 153 : 4636 4648.
23. Tsuji M, Bergmann CC, Takita-Sonoda Y, et al. Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice. J Virol 1998 72 : 6907 6910.
24. Schneider J, Gilbert SC, Blanchard TJ, et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 1998 4 : 397 402.
25. Sedegah M, Jones TR, Kaur M, et al. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc Natl Acad Sci USA 1998 95 : 7648 7653.
26. Sedegah M, Weiss W, Sacci JB Jr., et al. Improving protective immunity induced by DNA-based immunization: priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus. J Immunol 2000 164 : 5905 5912.
27. Bruña-Romero O, González-Aseguinolaza G, Hafalla JC, Tsuji M Nussenzweig RS. Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proc Natl Acad Sci USA 2001 98 : 11491 11496.
28. Rogers WO, Baird JK, Kumar A, et al. Multistage multiantigen heterologous prime boost vaccine for Plasmodium knowlesi malaria provides partial protection in rhesus macaques. Infect Immun 2001 69 : 5565 5572.
29. Schneider J, Langermans JA, Gilbert SC, et al. A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees. Vaccine 2001 19 : 4595 4602.
30. Gilbert SC, Schneider J, Hannan CM, et al. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine 2002 20 : 1039 1045.
31. Rogers WO, Weiss WR, Kumar A, et al. Protection of rhesus macaques against lethal Plasmodium knowlesi malaria by a heterologous DNA priming and poxvirus boosting immunization regimen. Infect Immun 2002 70 : 4329 4335.
32. Sedegah M, Brice GT, Rogers WO, et al. Persistence of protective immunity to malaria induced by DNA priming and poxvirus boosting: characterization of effector and memory CD8(+)-T-cell populations. Infect Immun 2002 70 : 3493 3499.
33. Sedegah M, Belmonte M, Epstein JE, et al. Successful induction of CD8 T cell-dependent protection against malaria by sequential immunization with DNA and recombinant poxvirus of neonatal mice born to immune mothers. J Immunol 2003 171 : 3148 3153.
34. Anderson RJ, Hannan CM, Gilbert SC, et al. Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus. J Immunol 2004 172 : 3094 3100.
35. Bruña-Romero O, Rocha CD, Tsuji M Gazzinelli RT. Enhanced protective immunity against malaria by vaccination with a recombinant adenovirus encoding the circumsporozoite protein of Plasmodium lacking the GPI-anchoring motif. Vaccine 2004 22 : 3575 3584.
36. Hutchings CL, Gilbert SC, Hill AV Moore AC. Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity. J Immunol 2005 175 : 599 606.
37. Cottingham MG, van Maurik A, Zago M, et al. Different levels of immunogenicity of two strains of Fowlpox virus as recombinant vaccine vectors eliciting T-cell responses in heterologous prime-boost vaccination strategies. Clin Vaccine Immunol 2006 13 : 747 757.
38. Strauss R, Hüser A, Ni S, et al. Baculovirus-based vaccination vectors allow for efficient induction of immune responses against Plasmodium falciparum circumsporozoite protein. Mol Ther 2007 15 : 193 202.
39. Draper SJ, Moore AC, Goodman AL, et al. Effective induction of high-titer antibodies by viral vector vaccines. Nat Med 2008 14 : 819 821.
40. Reyes-Sandoval A, Sridhar S, Berthoud T, et al. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur J Immunol 2008 38 : 732 741.
41. Sridhar S, Reyes-Sandoval A, Draper SJ, et al. Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A. J Virol 2008 82 : 3822 3833.
42. Liu J, O'Brien KL, Lynch DM, et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009 457 : 87 91.
43. Amante FH, Crewther PE, Anders RF Good MF. A cryptic T cell epitope on the apical membrane antigen 1 of Plasmodium chabaudi adami can prime for an anamnestic antibody response: implications for malaria vaccine design. J Immunol 1997 159 : 5535 5544.
44. Egan A, Waterfall M, Pinder M, Holder A Riley E. Characterization of human T- and B-cell epitopes in the C terminus of Plasmodium falciparum merozoite surface protein 1: evidence for poor T-cell recognition of polypeptides with numerous disulfide bonds. Infect Immun 1997 65 : 3024 3031.
45. Rathore D, Nagarkatti R, Jani D, et al. An immunologically cryptic epitope of Plasmodium falciparum circumsporozoite protein facilitates liver cell recognition and induces protective antibodies that block liver cell invasion. J Biol Chem 2005 280 : 20524 20529.
46. Stephens R, Albano FR, Quin S, et al. Malaria-specific transgenic CD4(+) T cells protect immunodeficient mice from lethal infection and demonstrate requirement for a protective threshold of antibody production for parasite clearance. Blood 2005 106 : 1676 1684.
47. Plebanski M, Lee EA Hill AV. Immune evasion in malaria: altered peptide ligands of the circumsporozoite protein. Parasitology 1997 115 (Suppl. S55 S66.
48. Moore AC, Gallimore A, Draper SJ, Watkins KR, Gilbert SC Hill AV. Anti-CD25 antibody enhancement of vaccine-induced immunogenicity: increased durable cellular immunity with reduced immunodominance. J Immunol 2005 175 : 7264 7273.
49. Steers N, Schwenk R, Bacon DJ, Berenzon D, Williams J Krzych U. The immune status of Kupffer cells profoundly influences their responses to infectious Plasmodium berghei sporozoites. Eur J Immunol 2005 35 : 2335 2346.
50. Bejon P, Mwacharo J, Kai O, et al. The induction and persistence of T cell IFN-gamma responses after vaccination or natural exposure is suppressed by Plasmodium falciparum. J Immunol 2007 179 : 4193 4201.
51. Usynin I, Klotz C Frevert U. Malaria circumsporozoite protein inhibits the respiratory burst in Kupffer cells. Cell Microbiol 2007 9 : 2610 2628.
52. Hisaeda H, Tetsutani K, Imai T, et al. Malaria parasites require TLR9 signaling for immune evasion by activating regulatory T cells. J Immunol 2008 180 : 2496 2503.
53. Casares S Richie TL. Immune evasion by the malaria parasite: a challenge for vaccine development. Cur Opin Immunol 2009 21 : 321 330.
54. Doolan DL Hoffman SL. The complexity of protective immunity against liver-stage malaria. J Immunol 2000 165 : 1453 1462.
55. Kawai T Akira S. Antiviral signaling through pattern recognition receptors. J Biochem 2007 141 : 137 145.
56. Pombo DJ, Lawrence G, Hirunpetcharat C, et al. Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 2002 360 : 610 617.
57. Tine JA, Lanar DE, Smith DM, et al. NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infect Immun 1996 64 : 3833 3844.
58. Barouch DH, Pau MG, Custers JH, et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 2004 172 : 6290 6297.
59. Sumida SM, Truitt DM, Kishko MG, et al. Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol 2004 78 : 2666 2673.
60. Catanzaro AT, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 2006 194 : 1638 1649.
61. Thorner AR, Vogels R, Kaspers J, et al. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa. J Clin Microbiol 2006 44 : 3781 3783.
62. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008 372 : 1881 1893.
63. Perreau M, Pantaleo G Kremer E. Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J Exp Med 2008 205 : 2717 2725.
64. Meyer H, Sutter G Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 1991 72 (Pt 5 1031 1038.
65. Cosma A, Nagaraj R, Bühler S, et al. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 2003 22 : 21 29.
66. Tartaglia J, Perkus ME, Taylor J, et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 1992 188 : 217 232.
67. Edghill-Smith Y, Venzon D, Karpova T, et al. Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques. J Infect Dis 2003 188 : 1181 1191.
68. Poulet H, Minke J, Pardo MC, Juillard V, Nordgren B Audonnet JC. Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform. Vaccine 2007 25 : 5606 5612.
69. Kinloch-de Loes S, Hoen B, Smith DE, et al. Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis 2005 192 : 607 617.
70. Emery S, Kelleher AD, Workman C, et al. Influence of IFNgamma co-expression on the safety and antiviral efficacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapy. Hum Vaccin 2007 3 : 260 267.
71. Ockenhouse CF, Sun PF, Lanar DE, et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis 1998 177 : 1664 1673.
72. Yang ZY, Wyatt LS, Kong WP, Moodie Z, Moss B Nabel GJ. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol 2003 77 : 799 803.
73. Harrop R, Drury N, Shingler W, et al. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol Immunother 2008 57 : 977 986.
74. Marshall JL, Gulley JL, Arlen PM, et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 2005 23 : 720 731.
75. Arlen PM, Gulley JL, Madan RA, Hodge JW Schlom J. Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. Crit Rev Immunol 2007 27 : 451 462.
76. Gómez CE, Nájera JL, Domingo-Gil E, Ochoa-Callejero L, González-Aseguinolaza G Esteban M. Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice. J Gen Virol 2007 88 : 2473 2478.
77. Mooij P, Balla-Jhagjhoorsingh SS, Koopman G, et al. Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates. J Virol 2008 82 : 2975 2988.
78. Zhang X, Cassis-Ghavami F, Eller M, et al. Direct comparison of antigen production and induction of apoptosis by canarypox virus and modified vaccinia virus Ankara-human immunodeficiency virus vaccine vectors. J Virol 2007 81 : 7022 7033.
79. Nájera JL, Gómez CE, Domingo-Gil E, Gherardi MM Esteban M. Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene. J Virol 2006 80 : 6033 6047.
80. Franchini G, Gurunathan S, Baglyos L, Plotkin S Tartaglia J. Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert Rev Vaccines 2004 3 : S75 S88.
81. Nichols WW, Lardenoije R, Ledwith BJ, et al. Propagation of adenoviral vectors: use of PER.C6 cells. In Curiel D Douglas J (eds Adenoviral Vectors for Gene Therapy. San Diego, Academic Press, 2002 : 129 166.
82. Brough DE, Lizonova A, Hsu C, Kulesa VA Kovesdi I. A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol 1996 70 : 6497 6501.
83. Nwanegbo E, Vardas E, Gao W, et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of the Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 2004 11 : 351 357.
84. Robertson M, Kublin J, Leavitt R, et al. Safety review of Merck's adenovirus type-5 (Ad5) HIV vaccines in healthy adults. 12th Conference on Retroviruses and Opportunistic Infections, Poster #503, Abstract #G-109 2005.
85. Ophorst OJ, Radosević K, Havenga MJ, et al. Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice. Infect Immun 2006 74 : 313 320.
86. Vogels R, Zuijdgeest D, van Rijnsoever R, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003 77 : 8263 8271.
87. Havenga M, Vogels R, Zuijdgeest D, et al. Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells. J Gen Virol 2006 87 (Pt 8 2135 2143.
88. Cheng C, Gall JG, Kong WP, et al. Mechanism of Ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells. PLoS Pathog 2007 3 : e25.
89. Tatsis N Ertl H. Adenoviruses as vaccine vectors. Mol Ther 2004 10 : 616 629.
90. Reyes-Sandoval A, Harty JT Todryk SM. Viral vector vaccines make memory T cells against malaria. Immunology 2007 121 : 158 165.
91. Koup R, Lamoreaux L, Zarkowsky D, et al. Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials. J Virol 2009 83 : 6318 6322.
92. Yang TC, Millar J, Groves T, et al. The CD8+ T cell population elicited by recombinant adenovirus displays a novel partially exhausted phenotype associated with prolonged antigen presentation that nonetheless provides long-term immunity. J Immunol 2006 176 : 200 210.
93. Brown M, Zhang Y, Dermine S, et al. Dendritic cells infected with recombinant fowlpox virus vectors are potent and long-acting stimulators of transgene-specific class I restricted T lymphocyte activity. Gene Ther 2000 7 : 1680 1689.
94. Chen Q, Pettersson F, Vogt AM, et al. Immunization with PfEMP1-DBL1alpha generates antibodies that disrupt rosettes and protect against the sequestration of Plasmodium falciparum-infected erythrocytes. Vaccine 2004 22 : 2701 2712.
95. Tao D, Barba-Spaeth G, Rai U, Nussenzweig V, Rice CM Nussenzweig RS. Yellow fever 17D as a vaccine vector for microbial CTL epitopes: protection in a rodent malaria model. J Exp Med 2005 201 : 201 209.
96. Qiao C, Wang B, Zhu X, Li J Xiao X. A novel gene expression control system and its use in stable, high-titer 293 cell-based adeno-associated virus packaging cell lines. J Virol 2002 76 : 13015 13027.
97. Logan GJ, Wang L, Zheng M, Cunningham SC, Coppel RL Alexander IE. AAV vectors encoding malarial antigens stimulate antigen-specific immunity but do not protect from parasite infection. Vaccine 2007 25 : 1014 1022.
98. Donsante A, Miller D, Li T, et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science 2007 317 : 477.
99. Inagaki K, Piao C, Kotchey N, Wu X Nakai H. Frequency and spectrum of genomic integration of recombinant adeno-associated virus serotype 8 vector in neonatal mouse liver. J Virol 2008 82 : 9513 9524.
100. Romano G. Current development of adeno-associated viral vectors. Drug News Perspect 2005 18 : 311 316.
101. Gilbert SC, Plebanski M, Harris SJ, et al. A protein particle vaccine containing multiple malaria epitopes. Nat Biotechnol 1997 15 : 1280 1284.
102. Hill AV. Pre-erythrocytic malaria vaccines: towards greater efficacy. Nat Rev Immunol 2006 6 : 21 32.
103. Moorthy VS, McConkey S, Roberts M, et al. Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 2003 21 : 1995 2002.
104. Moorthy VS, Pinder M, Reece WH, et al. Safety and immunogenicity of DNA/modified vaccinia virus Ankara malaria vaccination in African adults. J Infect Dis 2003 188 : 1239 1244.
105. Moorthy VS, Imoukhuede EB, Milligan P, et al. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med 2004 1 : e33.
106. Dunachie SJ, Walther M, Epstein JE, et al. A DNA prime-modified vaccinia virus Ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect Immun 2006 74 : 5933 5942.
107. Webster DP, Dunachie S, McConkey S, et al. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 2006 24 : 3026 3034.
108. Vuola JM, Keating S, Webster DP, et al. Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J Immunol 2005 174 : 449 455.
109. Webster DP, Dunachie S, Vuola JM, et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci USA 2005 102 : 4836 4841.
110. Bejon P, Andrews L, Andersen RF, et al. Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J Infect Dis 2005 191 : 619 626.
111. Moorthy VS, Imoukhuede EB, Keating S, et al. Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. J Infect Dis 2004 189 : 2213 2219.
112. Bejon P, Mwacharo J, Kai O, et al. A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clin Trials 2006 1 : e29.
113. Bejon P, Ogada E, Mwangi T, et al. Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS ONE 2007 2 : e707.
114. Keating SM, Bejon P, Berthoud T, et al. Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J Immunol 2005 175 : 5675 5680.
115. Romero P, Maryanski JL, Corradin G, Nussenzweig RS, Nussenzweig V Zavala F. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 1989 341 : 323 326.
116. Khusmith S, Sedegah M Hoffman SL. Complete protection against Plasmodium yoelii by adoptive transfer of a CD8+ cytotoxic T-cell clone recognizing sporozoite surface protein 2. Infect Immun 1994 62 : 2979 2983.
117. Luty AJ, Lell B, Schmidt-Ott R, et al. Interferon-gamma responses are associated with resistance to reinfection with Plasmodium falciparum in young African children. J Infect Dis 1999 179 : 980 988.
118. Ong'echa JM, Lal AA, Terlouw DJ, et al. Association of interferon-gamma responses to pre-erythrocytic stage vaccine candidate antigens of Plasmodium falciparum in young Kenyan children with improved hemoglobin levels: XV. Asembo Bay Cohort Project. Am J Trop Med Hyg 2003 68 : 590 597.
119. John CC, Moormann AM, Sumba PO, Ofulla AV, Pregibon DC Kazura JW. Gamma interferon responses to Plasmodium falciparum liver-stage antigen 1 and thrombospondin-related adhesive protein and their relationship to age, transmission intensity, and protection against malaria. Infect Immun 2004 72 : 5135 5142.
120. Reece WH, Pinder M, Gothard PK, et al. A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med 2004 10 : 406 410.
121. Todryk SM, Bejon P, Mwangi T, et al. Correlation of memory T cell responses against TRAP with protection from clinical malaria, and CD4 CD25 high T cells with susceptibility in Kenyans. PLoS ONE 2008 3 : e2027.
122. Schofield L, Villaquiran J, Ferreira A, Schellekens H, Nussenzweig R Nussenzweig V. Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature 1987 330 : 664 666.
123. Doolan DL Hoffman SL. IL-12 and NK cells are required for antigen-specific adaptive immunity against malaria initiated by CD8+ T cells in the Plasmodium yoelii model. J Immunol 1999 163 : 884 892.
124. Precopio ML, Betts MR, Parrino J, et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J Exp Med 2007 204 : 1405 1416.
125. Rodríguez A, Goudsmit J, Companjen A, et al. Impact of recombinant adenovirus serotype 35 priming versus boosting of a Plasmodium falciparum protein: characterization of T- and B-cell responses to liver-stage antigen 1. Infect Immun 2008 76 : 1709 1718.
126. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000 408 : 605 609.
127. Lin T, Liang S, Meng F, et al. Enhanced immunogenicity and antitumour effects with heterologous prime-boost regime using vaccines based on MG7-Ag mimotope of gastric cancer. Clin Exp Immunol 2006 144 : 319 325.
128. McConnell MJ, Hanna PC Imperiale MJ. Adenovirus-based prime-boost immunization for rapid vaccination against anthrax. Mol Ther 2007 15 : 203 210.
129. Chen P, Tian J, Kovesdi I Bruder JT. Promoters influence the kinetics of transgene expression following adenovector gene delivery. J Gene Med 2008 10 : 123 131.
130. Doolan DL, Southwood S, Freilich DA, et al. Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proc Natl Acad Sci USA 2003 100 : 9952 9957.
131. Kariu T, Ishino T, Yano K, Chinzei Y Yuda M. CelTOS, a novel malarial protein that mediates transmission to mosquito and vertebrate hosts. Mol Microbiol 2006 59 : 1369 1379.
132. Ophorst OJ, Radosević K, Klap JM, et al. Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant. Vaccine 2007 25 : 6501 6510.
133. Worgall S, Busch A, Rivara M, et al. Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses. J Virol 2004 78 : 2572 2580.
134. Xin KQ, Jounai N, Someya K, et al. Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV. Gene Ther 2005 12 : 1769 1777.
135. Roberts DM, Nanda A, Havenga MJ, et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 2006 441 : 239 243.
136. Yoshida S, Kondoh D, Arai E, et al. Baculovirus virions displaying Plasmodium berghei circumsporozoite protein protect mice against malaria sporozoite infection. Virology 2003 316 : 161 170.
137. Worgall S, Krause A, Rivara M, et al. Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid. J Clin Inves 2005 115 : 1281 1289.